Dr. Edgardo Santos' Interview with Richard Kim, MD
Update: 2025-08-25
Description
Interviews with Summit Director Edgardo S. Santos Castillero, MD, FACP, FASCO
NOSCM 2024 | New Orleans SummerCancer Meeting
Dr. Edgardo Santos' Interview with Richard Kim, MD
Dr. Kim reported that the ESO-EFFECT trial demonstratedsuperior survival and progression-free outcomes with a perioperative chemo-fluid regimen versus neoadjuvant chemo-radiation in resectable esophageal cancer, though definitive data on adjuvant immunotherapy are still lacking. For gastric cancer, he highlighted FDA approval of the HER2-targeted ADC trastuzumab deruxtecan and emerging targets like Claudin 18.2 and FGFR2B, as well as the START study exploring chemo-immunotherapy-anti-TIGIT combinations in patients with CPS >1.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
